Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations 177Lu-PSMA-617 - Radioligand therapy target PSMA Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) NCT04689828 PSMAfore (CAAA617B12302) Metastatic castration-resistant prostate cancer, pre-taxane Phase 3 450 Radiographic Progression Free Survival (rPFS) Arm 1: Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used Arm 2: For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used mCRPC patients that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings Primary Analysis: 2022 Final Analysis: 2025 NCT04720157 PSMAddition (CAAA617C12301) Metastatic hormone sensitive prostate cancer Phase 3 1126 Radiographic Progression Free Survival (rPFS) Arm 1: 177Lu-PSMA-617 Participant will receive 7.4 GBq (+/- 10%) 177Lu-PSMA- 617, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Arm 2: For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) Primary Analysis: 2024 Publication TBD 110 Investor Relations | Q3 2021 Results TBD 1 NOVARTIS | Reimagining Medicine

View entire presentation